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Background
Attrition from randomised trials can introduce bias and
reduce study power affecting the generalisability, valid-
ity, and reliability of results [1]. Many strategies are
used by trialists to reduce attrition, including motivating
and engaging participants and sites to optimise data
return or compliance to follow-up procedures [2].
Objective
To quantify the effect of strategies to reduce attrition
from randomised trials in any healthcare setting.
Methods
Included studies were randomised evaluations of strategies
to reduce attrition embedded within randomised trials
from all disease areas and settings. The following sources
were searched for eligible studies [3]: MEDLINE (1950 to
present), EMBASE (1980 to present), PsycINFO (1806 to
present), DARE (most recent issue), CENTRAL (most
recent issue), CINAHL (1981 to present), C2-SPECTR
(most recent date), and ERIC (1966- present), Cochrane
Methodology Register, Current Controlled Trials metaR-
egister, WHO trials platform, Society for Clinical Trials
(SCT) conference proceedings (1980-2010), and publica-
tion reference lists. A survey of all UK clinical trials units
(CTU) was also conducted to identify studies.
Two authors reviewed potentially eligible titles and
abstracts. Data extracted were checked by two authors.
Study investigators were contacted for missing data.
Risk of bias was assessed using the Cochrane risk of
bias tool. Data were entered into RevMan5 and pooled
using the fixed effect model. Heterogeneity was explored
to determine whether some types of strategies to reduce
attrition were more effective than others. The analyses
focused on the primary endpoint of attrition.
Results
From 19,281 abstracts 31 unique RCTs were identified
from the following sources: MEDLINE, CENTRAL,
CINAHL n=9; SCT abstracts 1980-2010 n=4; reference
lists of relevant reviews n=7; and of included trials n=8
(7 duplicates); word of mouth n=4; and CTUs survey
n=6. Six types of strategies to reduce attrition were
identified: a) communication i.e. email, letters signed by
different study personnel, type of post, and delivery
method; b) questionnaire length i.e. short versus long; c)
incentives i.e. monetary incentives, offers of monetary
incentives or vouchers, and gifts; d) case management i.
e. trial assistants assigned to manage participant follow-
up; e) behavioural e.g. workshops giving participants
information about goal setting; and f) methodological
interventions e.g. blinded versus open trials. Final results
of the review will be presented.
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